TNF and congenital rubella syndrome: The release of TNFα, an important macrophage-activating molecule that is associated with CRS severity in MM patients treated with anti-BCMA CAR-T cells [5,13], was reduced in ARI2hIL-15 compared to ARI2hIL-2 (Figure 7B).